AR2011 is a stroma-targeted, tumor microenvironment responsive, oncolytic adenovirus (OAdV) whose replication is driven by a triple hybrid promoter based on a 0.5 Kb selected fragment of the SPARC promoter combined with hypoxia and NFkB-responsive elements; a parental version of this OAdV showed a remarkable efficacy in preclinical models of ovarian cancer [18]. The gene discussed is SPARC; the disease is neoplasm.